Haduvio Opportunity Positions Trevi (TRVI) for Multibagger Gains, Says Morgan Stanley
Trevi Therapeutics Inc. (NASDAQ:TRVI) is one of the best multibagger stocks to invest in right now.
Trevi Therapeutics Inc. (TRVI)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Rubric Capital Management David Rosen | 8,531,860 | $46,669,274 | +88% | 0.7% |
| 2. | Vivo Capital Albert Cha And Frank Kung | 4,487,903 | $24,548,829 | +29% | 2.51% |
| 3. | Woodline Partners Michael Rockefeller And Karl Kroeker | 4,046,435 | $22,133,999 | +97% | 0.12% |
| 4. | Siren L.L.C. Raymond Debbane | 3,938,793 | $21,545,198 | +38% | 1.11% |
| 5. | Octagon Capital Advisors Ting Jia | 3,672,000 | $20,085,840 | +11% | 4.41% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.90 | 948,948 | $1,803,001.20 | 948,948 | 2022-04-11 | Filing | |
| $1.90 | 2,631,578 | $4,999,998.20 | 10,421,428 | 2022-04-11 | Filing | |
| $1.90 | 948,948 | $1,803,001.20 | 948,948 | 2022-04-11 | Filing | |
| $1.90 | 2,631,578 | $4,999,998.20 | 10,421,428 | 2022-04-11 | Filing | |
| $1.90 | 948,948 | $1,803,001.20 | 948,948 | 2022-04-11 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $6.60 | 2,631 | $17,364.60 | 221,373 | 2025-03-25 | Filing | |
| $6.58 | 5,263 | $34,624.75 | 213,313 | 2025-03-21 | Filing | |
| $7.15 | 4,350 | $31,101.63 | 76,900 | 2025-03-10 | Filing | |
| $6.73 | 76,963 | $517,776.28 | 81,250 | 2025-03-10 | Filing | |
| $3.04 | 1,840 | $5,586.61 | 213,313 | 2024-09-09 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,048,102 | $9,590,133 | 0.14% | |
| 2. | 620,464 | $5,677,246 | 0.17% | |
| 3. | 79,000 | $722,850 | 0.34% | |
| 4. | 36,502 | $333,993 | 0.03% | |
| 5. | 35,100 | $321,165 | 0.08% |
News See All
15 Best Multibagger Stocks to Invest in Right Now
Just as a single diamond can outshine a handful of pebbles, a well-chosen multibagger can transform an ordinary portfolio into an extraordinary one.
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q2 2025 Earnings Call Transcript
Operator: Good afternoon, and welcome to the Trevi Therapeutics Second Quarter 2025 Earnings Conference Call. [Operator Instructions] Please note this event is being recorded.
Oppenheimer Raises Price Target for Trevi Therapeutics by $3
In a research note, the analyst informs investors that Haduvio's favorable topline Phase 2b news strengthens the company's case for addressing idiopathic pulmonary fibrosis persistent cough, for which...
Oppenheimer Boosts Trevi Therapeutics (TRVI) PT to $23, Cites Positive Haduvio Trial Results
On Tuesday, Oppenheimer increased its price target for Trevi Therapeutics Inc. (NASDAQ:TRVI) to $23 from $20, while maintaining an Outperform rating.
H.C. Wainwright Initiates Coverage of Trevi Therapeutics (TRVI) With Buy Rating
On May 28, Oren Livnat, an analyst from H.C. Wainwright initiated coverage of Trevi Therapeutics, Inc. (NASDAQ:TRVI) with a Buy rating and a $21 price target.
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q1 2025 Earnings Call Transcript
Operator: Good afternoon and welcome to the Trevi Therapeutics First Quarter 2025 Earnings Conference Call. At this time, all participants will be in a listen-only mode.
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q4 2024 Earnings Call Transcript
Operator: Good afternoon and welcome to the Trevi Therapeutics Fourth Quarter and Year End 2024 Earnings Conference Call. At this time, all participants will be in listen-only mode.
Why Trevi Therapeutics (TRVI) Is Advancing Today
With Trevi poised to soon announce data from a trial of its Haduvio drug as a treatment for refractory chronic cough (RCC), Stifel predicts that the readout will be positive.
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q3 2024 Earnings Call Transcript
Operator: Good afternoon, and welcome to the Trevi Therapeutics Third Quarter 2024 Earnings Conference Call. At this time, all participants will be in listen-only mode.
Hedge Fund Resource Center Billionaire Hedge Funds
